These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37302449)

  • 1. Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial.
    Ben-Horin S; Salomon N; Karampekos G; Viazis N; Lahat A; Ungar B; Eliakim R; Kuperstein R; Kriger-Sharabi O; Reiss-Mintz H; Yanai H; Dotan I; Zittan E; Maharshak N; Hirsch A; Weitman M; Mantzaris GJ; Kopylov U
    Clin Gastroenterol Hepatol; 2024 Feb; 22(2):347-356.e6. PubMed ID: 37302449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study.
    Yanai H; Salomon N; Lahat A; Ungar B; Eliakim R; Kriger-Sharabi O; Reiss-Mintz H; Koslowsky B; Shitrit AB; Tamir-Degabli N; Dotan I; Zittan E; Maharshak N; Hirsch A; Ben-Horin S; Kopylov U
    Aliment Pharmacol Ther; 2023 Jul; 58(2):175-181. PubMed ID: 37157131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
    Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin-QingDai Combination as Treatment for Moderate-Severe Ulcerative Colitis.
    Ben-Horin S; Kopylov U; Salomon N
    Case Rep Gastroenterol; 2022; 16(3):563-568. PubMed ID: 36824698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-controlled Pilot Study.
    Banerjee R; Pal P; Penmetsa A; Kathi P; Girish G; Goren I; Reddy DN
    J Clin Gastroenterol; 2021 Sep; 55(8):702-708. PubMed ID: 32889959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
    Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
    Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin for maintenance of remission in ulcerative colitis.
    Kumar S; Ahuja V; Sankar MJ; Kumar A; Moss AC
    Cochrane Database Syst Rev; 2012 Oct; 10():CD008424. PubMed ID: 23076948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study.
    Singla V; Pratap Mouli V; Garg SK; Rai T; Choudhury BN; Verma P; Deb R; Tiwari V; Rohatgi S; Dhingra R; Kedia S; Sharma PK; Makharia G; Ahuja V
    J Crohns Colitis; 2014 Mar; 8(3):208-14. PubMed ID: 24011514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.
    Herfarth H; Barnes EL; Valentine JF; Hanson J; Higgins PDR; Isaacs KL; Jackson S; Osterman MT; Anton K; Ivanova A; Long MD; Martin C; Sandler RS; Abraham B; Cross RK; Dryden G; Fischer M; Harlan W; Levy C; McCabe R; Polyak S; Saha S; Williams E; Yajnik V; Serrano J; Sands BE; Lewis JD;
    Gastroenterology; 2018 Oct; 155(4):1098-1108.e9. PubMed ID: 29964043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis.
    Naganuma M; Sugimoto S; Mitsuyama K; Kobayashi T; Yoshimura N; Ohi H; Tanaka S; Andoh A; Ohmiya N; Saigusa K; Yamamoto T; Morohoshi Y; Ichikawa H; Matsuoka K; Hisamatsu T; Watanabe K; Mizuno S; Suda W; Hattori M; Fukuda S; Hirayama A; Abe T; Watanabe M; Hibi T; Suzuki Y; Kanai T;
    Gastroenterology; 2018 Mar; 154(4):935-947. PubMed ID: 29174928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
    Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis.
    Fiorino G; Sturniolo GC; Bossa F; Cassinotti A; di Sabatino A; Giuffrida P; Danese S
    Cells; 2019 May; 8(6):. PubMed ID: 31151306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial.
    Shen Z; Zheng K; Zou J; Gu P; Xing J; Zhang L; Zhu L; Shen H
    Trials; 2021 Jan; 22(1):55. PubMed ID: 33441157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
    Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
    Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial.
    Yarur AJ; Chiorean MV; Panés J; Jairath V; Zhang J; Rabbat CJ; Sandborn WJ; Vermeire S; Peyrin-Biroulet L
    J Crohns Colitis; 2024 Jun; 18(6):885-894. PubMed ID: 38245818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.